How a Sleep Apnea Drug Actually Gets Approved in Europe and Why Off-Label Prescribing Fills the Gap
What sleep apnea drug approval in Europe really means for the prescription your doctor can write
Europe's regulator never rejected the apnea drug; it called a separate indication redundant, and one BMI number decides whether your prescription is on-label, off-label or funded.
Sleep Apnea Drug Approval in Europe, Answered First
No medicine is licensed anywhere in Europe to treat the airway obstruction itself. That is the honest starting point for sleep apnea drug approval in Europe, and it is not the same as saying nothing can be prescribed. Two medicines hold an EU marketing authorisation for daytime sleepiness that persists despite CPAP. A third carries apnea trial data inside a weight-management licence. Your doctor can still prescribe outside a licence. Who pays is decided by your country, not by the European Medicines Agency.
The gap between "not licensed" and "cannot be prescribed" is where the confusion lives. Our overview of which sleep apnea medicines are actually approved in 2026 lists the molecules by name. This page explains the machinery: how a licence is granted, why one was refused, and which national door pays for use outside it.
- A licensed indication describes the product label. It is not a permission slip for your doctor.
- Marketing authorisation and reimbursement are separate decisions, taken by different bodies.
- Europe licenses medicines for residual sleepiness on top of CPAP, not for the obstruction itself.
Two Things Most Guides Get Wrong About Apnea Drugs in Europe
The first error treats "approved" as one global switch. It is not. The same molecule can be licensed on one continent and refused on the other.
In 2011 the European Medicines Agency restricted modafinil to narcolepsy alone. For obstructive sleep apnea, including patients still sleepy despite correct CPAP use, "the data on the effectiveness were not sufficient to outweigh the risks" (European Medicines Agency, 2011). That indication came off the European label. The American regulator kept modafinil approved for sleepiness in obstructive sleep apnea. Pitolisant runs the other way, EU-licensed since 2021 for excessive daytime sleepiness in adults with obstructive sleep apnea, with no equivalent US approval.
The second error looks precise, which makes it worse. A widely read UK guide states that tirzepatide was approved specifically for moderate-to-severe apnea in adults with obesity. The European label says nothing of the kind. Apnea appears there as a weight-related comorbidity, one of the conditions qualifying a patient with a body mass index between 27 and 30 for the weight-management indication. A qualifying criterion is not a therapeutic indication, and confusing the two changes what your prescriber and your payer conclude.
- Divergence runs both ways, so a US or Australian approval tells you little about your own prescription.
- A comorbidity criterion inside a weight licence is not a licensed apnea indication, even on identical evidence.
How Sleep Apnea Drug Approval in Europe Actually Works
A medicine reaches a European label through the centralised procedure: one application, one assessment, one authorisation valid in every member state. Here is that sequence.
1The company files
An application goes to the European Medicines Agency. When an authorised medicine seeks a new use, that is an extension of indication, filed as a type II variation.
2The CHMP assesses it
The Committee for Medicinal Products for Human Use works to a 210-active-day clock, paused whenever it sends the company questions. What it produces is an opinion, not a licence.
3The European Commission decides
The legally binding marketing authorisation is a European Commission decision following that opinion. Only here does the medicine hold an EU licence.
4The label is rewritten
Approved uses land in section 4.1 of the Summary of Product Characteristics, supporting trial data in section 5.1. The reasoning is published in the European Public Assessment Report.
5Your country decides the price
National payers run their own health technology assessment. Under the EU HTA Regulation 2021/2282 a joint clinical assessment is shared between member states, but funding stays national. The UK sits outside that system, holding its own MHRA licence.
Step five is the part of sleep apnea drug approval in Europe that patients are never told about. Social security law is national competence, not EU law. That is why a medicine authorised by the European Commission can be legal and unfunded in your country on the same day.
Sources: the European Medicines Agency (2024) for the trial population; the EMA variation assessment report (2025), citing Pugliese and colleagues, for prevalence near 17% in the general population and 40-70% in people with obesity; Benjafield and colleagues in The Lancet Respiratory Medicine (2019) for the global burden. The 210 days are the CHMP's own procedural clock.
- The committee gives an opinion. The European Commission grants the authorisation.
- Price and reimbursement are negotiated country by country, after the licence exists.
Why the Committee Refused a Separate Apnea Indication
The refusal was not a verdict on the molecule. On 13 December 2024 the CHMP assessed two studies in 469 adults with moderate-to-severe obstructive sleep apnea and obesity, then found a separate indication unnecessary because the use "is already covered by the approved indication for weight management" (European Medicines Agency, 2024).
The 141-page variation assessment report is blunter. It records "major objections to the introduction of a new indication in SmPC section 4.1", and notes that because "patients were instructed to suspend PAP use 7 days prior to endpoint assessment... it is unclear whether tirzepatide treatment brings additional benefit on top of adherent PAP" (European Medicines Agency variation assessment report, 2025). Study 1 randomised 234 participants, 120 to placebo. Study 2 randomised 235.
The effect itself was substantial. In SURMOUNT-OSA, tirzepatide, a GLP-1 and GIP receptor agonist, lowered the apnea-hypopnea index by an estimated 20.0 events per hour in participants not using PAP and 23.8 in those using it, both p<0.001. On the highest dose, 43.0% of participants in Study 1 and 51.5% in Study 2 met criteria for disease resolution, with mean AHI reductions reaching 62.8% (New England Journal of Medicine, 2024). We unpack what those weight-loss trial results really showed separately. The objection was redundancy and trial design, never effect size. This is the single most misread decision in sleep apnea drug approval in Europe.
The BMI threshold that quietly decides your prescription
The report confirms that "Obesity (BMI > 30 kg/m2) as such already qualifies for the approved weight management indication", and that patients are eligible "if presenting with a BMI of > 27 kg/m2 in the presence of at least one weight-related comorbid condition, e.g. OSA" (European Medicines Agency, 2025). One number decides everything.
| Your situation | EU status today | What it means in the room |
|---|---|---|
| BMI 30 or above, with sleep apnea | On-label | Obesity alone qualifies for the weight-management indication. |
| BMI 27 to under 30, apnea as the comorbidity | On-label | Apnea is the qualifying condition named in the label itself. |
| BMI under 27, with sleep apnea | Off-label | No licensed indication covers you, so consent and reimbursement rules apply. |
- The European committee called a separate apnea indication redundant, not ineffective.
- Suspending PAP for 7 days before the endpoint left the benefit over adherent CPAP unproven.
- At BMI 27 and above with apnea, this prescription is already on-label. Below 27, it is not.
What Europe Licenses Today, and What It Does Not
Europe already licenses two medicines connected to sleep apnea, and neither touches the obstruction. Solriamfetol received an EU marketing authorisation on 16 January 2020, pitolisant on 1 September 2021, both for excessive daytime sleepiness in adults with obstructive sleep apnea not satisfactorily treated by primary therapy such as CPAP. These are wakefulness medicines stacked on CPAP. Your Epworth Sleepiness Scale score is the target. Your apnea-hypopnea index is not.
| Molecule | European status | What it targets | Outside Europe |
|---|---|---|---|
| Tirzepatide | Licensed for weight management; separate apnea indication refused, December 2024 | Weight, and apnea only through weight loss | Standalone apnea indication granted in Australia, June 2025 |
| Solriamfetol | EU marketing authorisation, 16 January 2020 | Residual sleepiness despite primary therapy | Not addressed here |
| Pitolisant | EU marketing authorisation, 1 September 2021 | Residual daytime sleepiness in adults with OSA | No US approval for apnea |
| Modafinil | Apnea indication removed in 2011; narcolepsy only | Nothing apnea-related in the EU | Kept for sleepiness in OSA in the US |
| Sulthiame | Licensed in Europe for a childhood epilepsy; phase 2 in apnea | A carbonic anhydrase inhibitor, investigational here | Never registered in the US |
| AD109 | No announced EMA submission | Upper-airway muscle tone, investigational | US decision date set for 28 February 2027 |
In the phase 2 FLOW trial, sulthiame produced up to 47% fewer breathing interruptions per hour than placebo and improved overnight oxygen levels in 298 participants with moderate-to-severe apnea across four European countries (The Lancet, 2026). It already sits in European pharmacies as an epilepsy medicine. Licensing it for apnea would still need a full extension of indication, and the apnea evidence is only phase 2.
AD109 is the mirror image. In the phase 3 SynAIRgy trial it cut the AHI by at least half in 28.3% of participants against 17.7% on placebo (p<0.0001) among 646 adults, but all 69 centres sat in the United States or Canada, and the US decision date is 28 February 2027 with no announced European filing (American Journal of Respiratory and Critical Care Medicine, 2025). Our breakdown of the phase 3 results behind the airway-muscle pill covers the SynAIRgy and LunAIRo programme. A US filing date is not a European availability date.
- Two EU-licensed medicines are tied to apnea, and both treat residual sleepiness rather than the obstruction.
- Sulthiame is in Europe but unlicensed for apnea. AD109 was trialled without a single European site.
Off-Label Prescribing Is Legal, and Paying for It Is a Separate Question
Sleep apnea drug approval in Europe governs the label. It does not govern your doctor. EU pharmaceutical legislation, Directive 2001/83/EC, regulates marketing authorisation rather than the practice of medicine, and the European Court of Justice has confirmed that off-label prescribing "is not prohibited, or even regulated, by EU law". A doctor exercising clinical judgement may prescribe a licensed medicine outside its indication. That is hors AMM in France, Off-Label-Use in Germany, uso off-label in Italy.
Reimbursement is the harder door, and it is national. Each country runs a named legal mechanism with its own national competent authority behind it, and no EMA decision triggers any of them: ANSM in France, BfArM in Germany, AIFA in Italy, AEMPS in Spain.
| Country | Named off-label route | What it changes for you |
|---|---|---|
| France | Cadre de prescription compassionnelle (CPC), run by ANSM since 1 July 2021 | Where ANSM issues a favourable opinion, cover is immediate and automatic, for a renewable three-year period. |
| Germany | Off-label expert groups at BfArM under paragraph 35c SGB V, feeding the G-BA | Positive assessments land in Annex VI Part A, prescribable without prior sickness-fund approval. Negative ones land in Part B, excluded. |
| Italy | Legge 648/96 and the AIFA off-label lists | Listed uses are funded by the national health service. Written consent is required. |
| Spain | Real Decreto 1015/2009 | Sets the legal conditions for use outside the authorised label, consent included. |
| Netherlands, Finland | A consent rule rather than a named funding list | Documented verbal consent is accepted, instead of a signed form. |
Germany carries one extra route. The Nikolaus-Beschluss created paragraph 2(1a) SGB V, allowing a claim for life-threatening or comparably severe conditions with a not-remote prospect of benefit. Snoring alone does not meet that bar.
Consent and liability, the part that changes in the room
An off-label prescription shifts the paperwork and the risk. Written informed consent is legally mandated in Italy, Belgium, Germany, Poland, Spain and the Czech Republic, while the Netherlands and Finland accept documented verbal consent. Poland requires it before administration. There is no single EU consent rule, and courts accept prescriber liability more readily for off-label than on-label use. That is why a careful doctor hesitates, even when the evidence looks good.
- No EU law prohibits off-label prescribing, but national liability law still applies.
- France, Germany, Italy and Spain each have a named funding route, with different rules.
- Expect a written consent form in most member states, and a prescriber carrying more exposure.
A Five-Question Script for Your Next Appointment
Most people leave the consultation with a headline and no decision. These five questions turn that into ten usable minutes.
- Is this actually off-label for me? Ask your doctor to check your BMI against the label. At 27 or above with apnea as the comorbidity, the weight-management indication already covers you.
- If it is off-label, which national scheme applies? Name it: the CPC in France, paragraph 35c SGB V in Germany, Legge 648/96 in Italy, Real Decreto 1015/2009 in Spain.
- Am I being offered a wakefulness medicine or an apnea treatment? Solriamfetol and pitolisant are licensed for residual sleepiness, not for reducing events per hour.
- What does my sleep study show? Ask for the apnea-hypopnea index and oxygen desaturation figures from your polysomnography or home sleep apnea test.
- What do I use for the obstruction meanwhile? Licence timelines run in years. Your nights do not.
- Your BMI, not the news cycle, decides whether a prescription is on-label in Europe.
- Naming your country's off-label mechanism moves the answer from "no" to "let me check".
What Is Left for the Obstruction Itself
One group falls through every gap in sleep apnea drug approval in Europe: the reader with a BMI under 27, snoring or mild-to-moderate apnea, and no obesity to treat. No licensed medicine addresses them, and on the sulthiame and AD109 timelines none arrives soon.
Devices reach Europe by a different road. A nasal stent is a medical device under MDR 2017/745 and carries a CE mark, rather than a medicine assessed by the EMA through the centralised procedure. Different law, different clock. Back2Sleep is a CE-certified Class I soft silicone intranasal stent that keeps the nasal airway open during sleep, for snoring and mild-to-moderate obstructive sleep apnea. No prescription, no electricity, no tubing, and a starter kit of four sizes at around EUR 39 with a 30-day money-back window. It is not a treatment for severe apnea and not a replacement for CPAP.
Other non-drug routes share that regulatory family. A mandibular advancement device fitted by a dentist repositions the jaw; positional therapy stops you sleeping supine. Neither is a medicine, and neither waits on a CHMP opinion.
- Medicines and devices follow separate European routes, which is why device options exist and drugs do not.
- Below BMI 27 with mild-to-moderate disease, no licensed European medicine currently applies to you.
- With severe apnea, or on established CPAP, treat the drug pipeline as an addition and never a substitute.
What Back2Sleep Users Say
Frequently Asked Questions
Is there an approved drug for sleep apnea in Europe?
No medicine is licensed in Europe to treat the airway obstruction itself. Two are authorised for excessive daytime sleepiness that persists despite CPAP: solriamfetol since 16 January 2020 and pitolisant since 1 September 2021. Tirzepatide reaches apnea only through the weight-management indication, never as a standalone apnea licence.
Can my doctor prescribe a sleep apnea drug off-label in Europe?
Yes. EU law regulates marketing authorisation, not the practice of medicine, and the European Court of Justice has confirmed off-label prescribing is not prohibited, or even regulated, by EU law. Your doctor decides clinically and documents consent. National liability and professional-conduct rules still apply to that decision.
Will my health insurance pay for an off-label sleep apnea medication?
Only through a named national route. France reimburses automatically where ANSM issues a favourable cadre de prescription compassionnelle opinion. Germany routes it through paragraph 35c SGB V into G-BA Annex VI. Italy uses Legge 648/96, Spain Real Decreto 1015/2009. An EMA decision never triggers payment by itself.
Why is a sleep apnea drug approved in the US but not in Europe?
Regulators weigh the same dossier differently, and the divergence runs both ways. The EMA removed modafinil's apnea indication in 2011 on a negative benefit-risk balance while the American regulator kept it. Pitolisant is EU-licensed for sleepiness in apnea with no equivalent US apnea approval at all.
How long does EMA approval take for a new indication?
The CHMP works to a 210-active-day evaluation clock, paused each time it sends the company questions, so elapsed time is longer. Its output is a scientific opinion. The European Commission then grants the legally binding authorisation, and national price and reimbursement negotiations follow after that.
Do I need a home sleep apnea test before any treatment decision?
In practice, yes. Clinicians set treatment thresholds from an apnea-hypopnea index measured by polysomnography or a home sleep apnea test. The drug trials enrolled people with moderate-to-severe disease defined that way. Without those numbers, nobody can judge whether a medicine, a device or CPAP fits you.
When will a sleep apnea pill be available in Europe?
No date exists yet. AD109's phase 3 programme ran at 69 centres in the United States and Canada only, with a US decision date of 28 February 2027 and no announced European filing. Sulthiame is sold across Europe as an epilepsy medicine but holds only phase 2 apnea data.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.